Insider Selling: Illumina (NASDAQ:ILMN) Director Sells 220,000 Shares of Stock

Illumina, Inc. (NASDAQ:ILMN) Director Keith Meister sold 220,000 shares of the firm’s stock in a transaction that occurred on Thursday, May 28th. The shares were sold at an average price of $152.27, for a total value of $33,499,400.00. Following the completion of the transaction, the director owned 3,280,048 shares in the company, valued at approximately $499,452,908.96. This trade represents a 6.29% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link.

Illumina Price Performance

Shares of NASDAQ ILMN traded up $1.44 during midday trading on Monday, hitting $164.40. The stock had a trading volume of 2,190,450 shares, compared to its average volume of 1,870,323. The company has a market capitalization of $24.87 billion, a PE ratio of 29.89, a P/E/G ratio of 2.70 and a beta of 1.50. The stock has a 50 day simple moving average of $133.73 and a 200-day simple moving average of $132.09. Illumina, Inc. has a 1 year low of $78.79 and a 1 year high of $165.97. The company has a quick ratio of 1.36, a current ratio of 1.75 and a debt-to-equity ratio of 0.56.

Illumina (NASDAQ:ILMN) last released its earnings results on Thursday, April 30th. The life sciences company reported $1.15 earnings per share for the quarter, beating the consensus estimate of $1.05 by $0.10. The business had revenue of $1.09 billion for the quarter, compared to the consensus estimate of $1.07 billion. Illumina had a return on equity of 31.01% and a net margin of 19.42%.The business’s quarterly revenue was up 4.8% compared to the same quarter last year. During the same quarter last year, the business posted $0.97 earnings per share. Illumina has set its FY 2026 guidance at 5.150-5.300 EPS. On average, sell-side analysts expect that Illumina, Inc. will post 5.2 EPS for the current fiscal year.

Institutional Inflows and Outflows

Several hedge funds have recently bought and sold shares of the stock. MassMutual Private Wealth & Trust FSB boosted its stake in Illumina by 7.9% during the fourth quarter. MassMutual Private Wealth & Trust FSB now owns 1,081 shares of the life sciences company’s stock worth $142,000 after buying an additional 79 shares during the period. HighPoint Advisor Group LLC grew its stake in shares of Illumina by 3.7% in the fourth quarter. HighPoint Advisor Group LLC now owns 2,218 shares of the life sciences company’s stock valued at $291,000 after buying an additional 80 shares in the last quarter. Meeder Advisory Services Inc. grew its stake in shares of Illumina by 3.1% in the first quarter. Meeder Advisory Services Inc. now owns 2,822 shares of the life sciences company’s stock valued at $348,000 after buying an additional 85 shares in the last quarter. Toronto Dominion Bank grew its stake in shares of Illumina by 0.3% in the fourth quarter. Toronto Dominion Bank now owns 33,605 shares of the life sciences company’s stock valued at $4,407,000 after buying an additional 92 shares in the last quarter. Finally, Assetmark Inc. grew its stake in shares of Illumina by 10.2% in the third quarter. Assetmark Inc. now owns 1,039 shares of the life sciences company’s stock valued at $99,000 after buying an additional 96 shares in the last quarter. Hedge funds and other institutional investors own 89.42% of the company’s stock.

Illumina News Roundup

Here are the key news stories impacting Illumina this week:

• Positive Sentiment: Guggenheim raised its price target on Illumina to $180 from $170 and kept a Buy rating, signaling continued confidence in the company’s upside potential and valuation. Benzinga article
• Positive Sentiment: Integrated DNA Technologies said its oncology research workflows are now optimized on Illumina software, which could support broader adoption of Illumina’s ecosystem and strengthen its positioning in cancer research tools. Business Wire article
• Neutral Sentiment: Chief accounting officer Scott D. Ericksen sold a small number of shares under a pre-arranged Rule 10b5-1 plan; while routine, it adds to recent insider selling activity. SEC filing
• Negative Sentiment: Director Keith A. Meister sold a very large block of Illumina shares in multiple transactions around May 28-June 1, reducing his stake materially. Large insider sales can weigh on sentiment even when they do not necessarily reflect operational weakness. SEC filing

Analyst Upgrades and Downgrades

A number of equities analysts recently commented on ILMN shares. Daiwa Securities Group upgraded Illumina from a “neutral” rating to an “outperform” rating and set a $155.00 price objective on the stock in a research report on Thursday, May 14th. Citigroup upped their price objective on shares of Illumina from $80.00 to $95.00 and gave the company a “sell” rating in a report on Monday, May 4th. Royal Bank Of Canada assumed coverage on shares of Illumina in a research note on Thursday, May 14th. They set an “outperform” rating and a $170.00 target price on the stock. UBS Group reaffirmed a “neutral” rating and set a $135.00 target price on shares of Illumina in a research note on Friday, February 6th. Finally, Weiss Ratings lowered shares of Illumina from a “hold (c)” rating to a “hold (c-)” rating in a report on Wednesday, April 29th. Seven equities research analysts have rated the stock with a Buy rating, nine have given a Hold rating and two have issued a Sell rating to the company. According to data from MarketBeat, the company presently has a consensus rating of “Hold” and an average target price of $138.38.

Illumina Company Profile

Illumina, Inc (NASDAQ: ILMN) is a global life sciences company that develops, manufactures and markets integrated systems for the analysis of genetic variation and function. Headquartered in San Diego, California and founded in 1998, Illumina offers a range of sequencing and array-based technologies used by academic researchers, clinical laboratories, pharmaceutical and biotechnology companies, consumer genomics firms and agricultural researchers to enable discovery, translational research and clinical applications.

The company’s product portfolio includes next-generation sequencing (NGS) platforms and associated consumables, microarrays for genotyping and methylation analysis, library preparation kits and targeted assays.